Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions

Drug and Alcohol Dependence

Volumn 163, Issue , 2016, Pages 126-133

  Ciccarone, Daniel ^a   Unick, George Jay ^b   Cohen, Jenny K ^a   Mars, Sarah G ^a   Rosenblum, Daniel ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Black tar heroin; Drug markets; Heroin; Injection drug use; Soft tissue infection; Structural risk environment

Indexed keywords

DIAMORPHINE; NARCOTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG MARKETING; GOVERNMENT REGULATION; HEROIN DEPENDENCE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; INFECTION RATE; INFECTION RISK; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; COMMERCIAL PHENOMENA; COMPLICATION; COST; ECONOMICS; FEMALE; HUMAN; MIDDLE AGED; SOFT TISSUE INFECTIONS; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADULT; COMMERCE; COSTS AND COST ANALYSIS; FEMALE; HEROIN; HEROIN DEPENDENCE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NARCOTICS; SOFT TISSUE INFECTIONS; UNITED STATES; YOUNG ADULT;

EID: 84964863204     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.04.009     Document Type: Article

References (66)

1. Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project (HCUP) Introduction to the HCUP Nationwide Inpatient Sample (NIS) 2008, (from Rockville, MD). http://www.hcup-us.ahrq.gov/db/nation/nis/NIS_2008_INTRODUCTION.pdf.
2. Arkes J., Pacula R., Paddock S., Caulkins J.P., Reuter P. Why the DEA Stride Data Are Still Useful for Understanding Drug Markets 2008, (Nber Working Paper Series Retrieved from). http://www.nber.org/papers/w14224.pdf.
3. Bangsberg D.R., Rosen J.I., Aragon T., Campbell A., Weir L., Perdreau-Remington F. Clostridial myonecrosis cluster among injection drug users: a molecular epidemiology investigation. Arch. Intern. Med. 2002, 162:517-522. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=11871919.
4. Bardenheier B., Prevots D.R., Khetsuriani N., Wharton M. Tetanus surveillance-United States, 1995-1997. MMWR Surveill. Summ. 1998, 47:1-13. http://www.ncbi.nlm.nih.gov/pubmed/9665156.
5. Barrett, M., Lopez Gonzalez, L., Coffey, R., Levit, K., 2014. Population Denominator Data for Use with the HCUP Databases (Updated with 2013 Population Data). HCUP Methods Series Report # 2014-02 ONLINE. August 18, 2014. U.S. Agency for Healthcare Research and Quality. Available: . http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp.
6. Binswanger I.A., Kral A.H., Bluthenthal R.N., Rybold D.J., Edlin B.R. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin. Infect. Dis. 2000, 30:579-581. 10.1086/313703.
7. Binswanger I.A., Takahashi T.A., Bradley K., Dellit T.H., Benton K.L., Merrill J.O. Drug users seeking emergency care for soft tissue infection at high risk for subsequent hospitalization and death. J. Stud. Alcohol Drugs 2008, 69:924-932. http://www.ncbi.nlm.nih.gov/pubmed/18925351.
8. Bluthenthal R.N., Kral A.H., Gee L., Erringer E.A., Edlin B.R. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000, 14:605-611. http://www.ncbi.nlm.nih.gov/pubmed/10780722.
9. Bobashev G.V., Zule W.A. Modeling the effect of high dead-space syringes on the human immunodeficiency virus (HIV) epidemic among injecting drug users. Addiction 2010, 105:1439-1447. 10.1111/j.1360-0443.2010.02976.x.
10. Bourgois P., Schonberg J. Righteous Dopefiend 2009, University of California Press, Berkeley.
11. Caulkins J.P. Price and purity analysis for illicit drug: data and conceptual issues. Health Serv. Res. 2005, 25.
12. Center for Disease Control and Prevention Wound botulism-California, 1995. MMWR 1995, 44:889-892.
13. Ciccarone D., Bourgois P. Explaining the geographical variation of HIV among injection drug users in the United States. Subst. Use Misuse 2003, 38:2049-2063.
14. Ciccarone D., Harris M. Fire in the vein: heroin acidity and its proximal effect on users' health. Int. J. Drug Policy 2015, 26(11):1103-1110. Epub 2015 Apr 17. 10.1016/j.drugpo.2015.04.009.
15. Ciccarone D., Bourgois P., Murphy E., Kral A., Seal K., Moore J., Edlin B.R. Soft tissue infections among users of black tar heroin: a cross-methodological examination. Paper Presented at the Community Epidemiology Working Group Meeting 2000.
16. Ciccarone D., Bamberger J., Kral A., Hobart C.J., Moon A., Edlin B.R., et al. Soft tissue infections among injection drug users-San Francisco, California, 1996-2000. JAMA 2001, 285:2707-2709.
17. Ciccarone D., Unick G.J., Kraus A. Impact of South American heroin on the US heroin market 1993-2004. Int. J. Drug Policy 2009, 20:392-401. 10.1016/j.drugpo.2008.12.001.
18. Ciccarone D. Heroin in brown, black and white: structural factors and medical consequences in the US heroin market. Int. J. Drug Policy 2009, 20:277-282. 10.1016/j.drugpo.2008.08.003.
19. Cicero T.J., Ellis M.S. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxycontin. JAMA Psychiatry 2015, 72:424-430. 10.1001/jamapsychiatry.2014.3043.
20. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of oxycontin. N. Engl. J. Med. 2012, 367:187-189. 10.1056/NEJMc1204141.
21. Crane L.R., Levine D.P., Zervos M.J., Cummings G. Bacteremia in narcotic addicts at the Detroit Medical Center I. Microbiology, epidemiology, risk factors, and empiric therapy. Rev. Infect. Dis. 1986, 8:364-373. (Retrieved from). http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=3636987.
22. Curtis R., Friedman S.R., Neaigus A., Jose B., Goldstein M., Ildefonso G. Street-level drug markets: network structure and HIV risk. Social Netw. 1995, 17:229-249. 10.1016/0378-8733(95)00264-O.
23. Daniulaityte R., Carlson R.G., Kenne D.R. Initiation into pharmaceutical opioids and patterns of misuse: preliminary qualitative findings obtained by the Ohio Substance Abuse Monitoring Network. J. Drug Issues 2006, 36:787-809.
24. Dart R.C., Surratt H.L., Cicero T.J., Parrino M.W., Severtson S.G., Bucher-Bartelson B., Green J.L. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 2015, 372:241-248. 10.1056/NEJMsa1406143.
25. Dunbar N.M., Harruff R.C. Necrotizing fasciitis: manifestations, microbiology and connection with black tar heroin. J. Forensic Sci. 2007, 52:920-923. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=17524065.
26. Ebright J., Pieper B. Skin and soft tissue infections in injection drug users. Infect. Dis. Clin. North Am. 2002, 16:697-712. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=12371123.
27. Fink D.S., Lindsay S.P., Slymen D.J., Kral A.H., Bluthenthal R.N. Abscess and self-treatment among injection drug users at four California syringe exchanges and their surrounding communities. Subst. Use Misuse 2013, 48:523-531. 10.3109/10826084.2013.787094.
28. Gordon R.J., Lowy F.D. Bacterial infections in drug users. N. Engl. J. Med. 2005, 353:1945-1954. 10.1056/NEJMra042823.
29. Grau L.E., Arevalo S., Catchpool C., Heimer R. Expanding harm reduction services through a wound and abscess clinic. Am. J. Public Health 2002, 92:1915-1917. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve%26db=PubMed%26dopt=Citation%26list_uids=12453808.
30. Harris M., Rhodes T. Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs. Addiction 2012, 107:1090-1096. 10.1111/j.1360-0443.2011.03749.x.
31. Harris H.W., Young D.M. Care of injection drug users with soft tissue infections in San Francisco, California. Arch. Surg. 2002, 137:1217-1222. http://www.ncbi.nlm.nih.gov/pubmed/12413304.
32. Hope V.D., Parry J.V., Ncube F., Hickman M. Not in the vein: 'missed hits', subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. Int. J. Drug Policy 2016, 28:83-90. 10.1016/j.drugpo.2015.11.003.
33. Horowitz J.L. Should the DEA's STRIDE data be used for economic analyses of markets for illegal drugs?. J. Am. Stat. Assoc. 2001, 96:1254-1262. (Retrieved from). http://www.scopus.com/inward/record.url?eid=2-s2.0-1542469782%26partnerID=40%26md5=c1e6b3c4f63fc1ee93dc35f6ea7afd31.
34. Hurley S.F., Jolley D.J., Kaldor J.M. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997, 349:1797-1800. 10.1016/S0140-6736(96)11380-5.
35. Lankenau S.E., Teti M., Silva K., Jackson Bloom J., Harocopos A., Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int. J. Drug Policy 2012, 23:37-44. 10.1016/j.drugpo.2011.05.014.
36. Lloyd-Smith E., Wood E., Zhang R., Tyndall M.W., Montaner J.S., Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health 2008, 8:405. 10.1186/1471-2458-8-405.
37. Mars S.G., Bourgois P., Karandinos G., Montero F., Ciccarone D. Every 'never' I ever said came true: transitions from opioid pills to heroin injecting. Int. J. Drug Policy 2014, 25:257-266. 10.1016/j.drugpo.2013.10.004.
38. Maurer U., Kager C., Fellinger C., Loader D., Pollesbock A., Spitzer B., Jarisch R. Risk of anaphylaxis in opioid dependent persons: effects of heroin versus substitution substance. Subst. Abuse Treat. Prev. Policy 2014, 9:12. 10.1186/1747-597X-9-12.
39. Messac L., Ciccarone D., Draine J., Bourgois P. The good-enough science-and-politics of anthropological collaboration with evidence-based clinical research: four ethnographic case studies. Soc. Sci. Med. 2013, 10.1016/j.socscimed.2013.04.009.
40. Murphy E.L., DeVita D., Liu H., Vittinghoff E., Leung P., Ciccarone D.H., Edlin B.R. Risk factors for skin and soft-tissue abscesses among injection drug users: a case-control study. Clin. Infect. Dis. 2001, 33:35-40. 10.1086/320879.
41. Office of Drug Control Policy, 2012. Drug Availability Estimates in the United States, 2001-2006.
42. Office of Management and Budget 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas 2010, vol. 75:37246-39052. Federal Register.
43. Palfreyman S.J., Tod A.M., King B., Tomlinson D., Brazier J.E., Michaels J.A. Impact of intravenous drug use on quality of life for patients with venous ulcers. J. Adv. Nurs. 2007, 58:458-467. 10.1111/j.1365-2648.2007.04251.x.
44. Passaro D.J., Werner S.B., McGee J., Mac Kenzie W.R., Vugia D.J. Wound botulism associated with black tar heroin among injecting drug use rs. JAMA 1998, 279:859-863. (Retrieved from). http://www.ncbi.nlm.nih.gov/pubmed/9516001.
45. Peavy K.M., Banta-Green C.J., Kingston S., Hanrahan M., Merrill J.O., Coffin P.O. Hooked on prescription-type opiates prior to using heroin: results from a survey of syringe exchange clients. J. Psychoact. Drugs 2012, 44:259-265. 10.1080/02791072.2012.704591.
46. Phillips K.T., Stein M.D. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. Am. J. Drug Alcohol Abuse 2010, 36:92-97. 10.3109/00952991003592311.
47. Pieper B., Kirsner R.S., Templin T.N., Birk T.J. Injection drug use-an understudied cause of venous disease. Arch. Dermatol. 2007, 143:1305-1309. 10.1001/archderm.143.10.1305.
48. Pollini R.A., Gallardo M., Hasan S., Minuto J., Lozada R., Vera A., Zuniga M.L., Strathdee S.A. High prevalence of abscesses and self-treatment among injection drug users in Tijuana, Mexico. Int. J. Infect. Dis. 2010, 14(Suppl. 3):e117-122. 10.1016/j.ijid.2010.02.2238.
49. Rabe-Hesketh S., Skrondal A. Multilevel And Longitudinal Modeling Using Stata: Stata Corp 2013, College Station, TX.
50. Ramsay C.N., Stirling A., Smith J., Hawkins G., Brooks T., Hood J., Penrice G., Browning L.M., Ahmed S., on behalf of the NHS GGC, on behalf of the Scottish National Outbreak Control Teams An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill. 2010, 15(2). Available online: http://www.eurosurveillance.org/ViewArticle.aspx?
51. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int. J. Drug Policy 2009, 20:193-201. 10.1016/j.drugpo.2008.10.003.
52. Robinowitz N., Smith M.E., Serio-Chapman C., Chaulk P., Johnson K.E. Wounds on wheels: implementing a specialized wound clinic within an established syringe exchange program in Baltimore, Maryland. Am. J. Public Health 2014, 104:2057-2059. 10.2105/Ajph.2014.302111.
53. Rosenblum D., Unick G.J., Ciccarone D. The entry of Colombian-sourced heroin into the US market: the relationship between competition, price, and purity. Int. J. Drug Policy 2014, 25:88-95. 10.1016/j.drugpo.2013.10.003.
54. Sherman S.G., Smith L., Laney G., Strathdee S.A. Social influences on the transition to injection drug use among young heroin sniffers: a qualitative analysis. Int. J. Drug Policy 2002, 13:113-120. 10.1016/S0955-3959(02)00010-5.
55. Small W., Wood E., Lloyd-Smith E., Tyndall M., Kerr T. Accessing care for injection-related infections through a medically supervised injecting facility: qualitative study. Drug Alcohol Depend. 2008, 98:159-162. 10.1016/j.drugalcdep.2008.05.014.
56. Smith M.E., Robinowitz N., Chaulk P., Johnson K.E. Self-care and risk reduction habits in older injection drug users with chronic wounds: a cross-sectional study. Harm Reduct. J. 2014, 11:28. 10.1186/1477-7517-11-28.
57. Spijkerman I.J., v.A E., Mientjes G.H., Coutinho R.A., van den Hoek A. Human immunodeficiency virus infection and other risk factors for skin abscesses and endocarditis among injection drug users. J. Clin. Epidemiol. 1996, 49:1149-1154. (PMID: 8826995).
58. StataCorp Stata Statistical Software: Release 13 2013, College Station, TX.
59. Substance Abuse and Mental Health Services Administration Results from The2012 National Survey on Drug Use and Health: Summary of National Findings 2013, NSDUH, Rockville, MD, Series H-46, HHS Publication No. (SMA) 13-4795.
60. Takahashi T.A., Baerstein A., Binswanger I., Bradley K., Merrill J.O. Predictors of hospitalization for injection drug users seeking care for soft tissue infections. J. Gen. Intern. Med. 2007, 22:382-388.
61. Takahashi T.A., Maciejewski M.L., Bradley K. US hospitalizations and costs for illicit drug users with soft tissue infections. J. Behav. Health Serv. Res. 2010, 37:508-518. 10.1007/s11414-009-9177-z.
62. Toske S.G., Cooper S.D., Morello D.R., Hays P.A., Casale J.F., Casale E. Neutral heroin impurities from tetrahydrobenzylisoquinoline alkaloids. J. Forensic Sci. 2006, 51:308-320. (Retrieved from). http://onlinelibrary.wiley.com/store/10.1111/j.1556-4029.2006.00057.x/asset/j.1556-4029.2006.00057.x.pdf?v=1%26t=hri4mq70%26s=77a88e6d51e848c6305d4e415ff0e33a99ed5878.
63. US Drug Enforcement Administration, 2000. The Mexican Heroin Trade. (DEA-20014).
64. Unick G.J., Rosenblum D., Mars S., Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One 2013, 8:e54496. 10.1371/journal.pone.0054496.
65. Unick G., Rosenblum D., Mars S., Ciccarone D. The relationship between US heroin market dynamics and heroin-related overdose, 1992-2008. Addiction 2014, 109:1889-1898. 10.1111/add.12664.
66. Williamson N., Archibald C., Van Vliet J.S. Unexplained deaths among injection drug users: a case of probable Clostridium myonecrosis. CMAJ 2001, 165:609-611. (Retrieved from). http://www.ncbi.nlm.nih.gov/pubmed/11563214.